- PR Newswire•9 hours ago
NuVasive Receives First-Ever FDA Clearance For Cervical Interbody Implant System Used In More Than Two Levels
SAN DIEGO, March 29, 2017 /PRNewswire/ -- NuVasive, Inc. (NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the CoRoent® Small Interbody™ System indicated for intervertebral body fusion at multiple contiguous levels in the cervical spine. This marks the first U.S. clearance for a cervical cage to be used at up to four contiguous levels. "This FDA 510(k) clearance is another key milestone for NuVasive as we continue to deliver new innovation to the spine market.
- PR Newswire•9 days ago
SAN DIEGO, March 20, 2017 /PRNewswire/ -- NuVasive, Inc. (NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced updated guidance from the National Industry for Clinical Excellence (NICE) in the U.K. for lateral interbody fusion in the lumbar spine. NICE stated the evidence on efficacy for lateral interbody fusion is adequate in quality and quantity and the procedure may be used provided that standard arrangements are in place for clinical governance, consent and audit. The majority of the evidence submitted to and reviewed by the panel was peer-reviewed journal articles describing the now 14-year experience with and outcomes following the Company's eXtreme Lateral Interbody Fusion (XLIF®) procedure, the leading global lateral approach spine surgical technique.
- Zacks•14 days ago
NuVasive (NUVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NUVA : Summary for NuVasive, Inc. - Yahoo Finance
NuVasive, Inc. (NUVA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||70.00 x 100|
|Ask||80.00 x 200|
|Day's Range||74.92 - 75.53|
|52 Week Range||47.73 - 76.31|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||109.16|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|